GELNIQUE 3%
PeakNDATRANSDERMALGEL, METERED
Approved
Dec 2011
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GELNIQUE 3% is a transdermal gel formulation of oxybutynin, a small-molecule anticholinergic agent used to treat overactive bladder (OAB) symptoms including urgency, frequency, and urge incontinence. The metered-dose gel provides systemic delivery through skin absorption, avoiding first-pass metabolism and improving tolerability compared to oral formulations.
Peak
Peak lifecycle stage suggests mature, stable commercial operations with established field teams and potential for line extensions rather than aggressive growth campaigns.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GELNIQUE 3% offers stable, mature-stage pharmaceutical experience focused on commercial excellence, managed care negotiation, and patient adherence programs. Roles emphasize execution against established playbooks rather than launch innovation, making this suitable for professionals building expertise in peak-cycle brand management.
Brand ManagerField Sales Representative
Worked on GELNIQUE 3% at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.